Record Revenue & Profit: ₹3,184 million revenue (+53% QoQ, +91% YoY); ₹990 million PAT (+70% QoQ, +208% YoY).
Capacity Expansion: Unit 2 fully operational; 120 KL (Phase 1) & 37 KL (Phase 2) added for cardiovascular intermediates and contrast media.
R&D Investment: ₹40 crore committed for advanced intermediates, contrast media expansion, and CDMO projects.
Order Book & Outlook: Strong contract manufacturing order book with healthy customer demand; positive long-term growth visibility.
Financial Performance: EBITDA at ₹1,240 million (+79% QoQ, +127% YoY); 9M FY25 revenue ₹6,895 million (+31% YoY), EBITDA ₹2,378 million (+35% YoY).
Contrast Media Business: ₹3,028 million turnover (-17% YoY) due to external factors; new capacity expected to drive recovery.
Sustainability:70%-75% renewable energy usage via wind and solar.
Challenges: Contrast media offtake issues, potential product launch delays, but management confident in resolution.
Growth Plans: Pipeline of new product launches, expansion in pharmaceuticals & contrast media, and enhanced execution focus.
The company is on track to report its highest-ever annual net profit in FY25. As of the trailing twelve months (TTM) ending Q3 FY25, the company has recorded a net profit of ₹235 crore, already surpassing the full-year profit of ₹164 crore in FY24. With one quarter still to be reported, the company is poised for a record-breaking financial year, driven by strong operational performance, capacity expansions, and sustained business momentum.
🚨 Disclaimer:- These Are Not Any Recommendations To Buy OR Sell. The Above Views Are Just for Educational Purposes And Are My Personal Views. Please Do Your Own Analysis Before Taking Any Investment Decisions And Consult Your Financial Advisor. ✅📚
Comments